Opening Remarks at the WHO Technical Advisory Group on Leprosy

By Dr Nilesh Buddha, Officer-in-Charge, WHO South-East Asia

26 October 2026
Speech
Cairo
Reading time:
  • Dr. Patricia Deps, Chair of the WHO Technical Advisory Group on Leprosy

  • Members of the Technical Advisory Group

  • Dr. Benedetta Allegranzi, Director, Department of Health Promotion and Disease Prevention and Control, WHO Regional Office for the Eastern Mediterranean

  • Invited experts

  • Partners, and Colleagues 

Good morning to you all. 

I regret that I cannot be with you in person, and have asked the Team Leader of the Global Leprosy Programme to convey these remarks on my behalf. 

It is fitting that this meeting is held in the WHO Regional Office for the Eastern Mediterranean, home to Jordan — the first country in the world to be verified by WHO for eliminating leprosy. 

We meet at the midpoint of the Global Leprosy Strategy 2021 – 2030. 

And at this moment, the question is not only how far we have come. It is whether the person affected by leprosy remains at the center of everything we do. 

Since this Group last met, Chile has joined Jordan in the post-elimination phase. This reminds us that elimination is never purely an epidemiological milestone. 

It is the product of sustained political commitment, health systems that guarantee continuity of care, and freedom from stigma. 

More countries are now on this path, and WHO stands ready to support each as they prepare their elimination dossiers. 

The global leprosy update for 2025 shows both progress and an unfinished agenda. 

A record 203 countries and territories reported data. This is a testament to the commitment of Member States. 

New case detection continues to decline, with 167 356 new cases reported. 

Yet more than 9400 people were diagnosed only after visible disability had set in – more than the year before. Each was a diagnosis that came too late.  

The message is unmistakable: we must accelerate early detection. 

Contact screening, along with single-dose rifampicin post-exposure prophylaxis, gives us the means. 

Countries have shown that this approach is both feasible and acceptable. Our focus now must be scale. 

Progress on the ground needs sound science and sound guidance. 

Through its Technical Working Groups, the Global Leprosy Programme is advancing child-friendly formulations for treating children with leprosy in children, and it is strengthening the laboratory networks on which antimicrobial resistance surveillance depends. 

New work on the participation of persons affected by leprosy, and on managing complications, carries this person-centered agenda forward. 

Keeping clinical expertise alive, and referral pathways intact, is itself person-centered care, allowing for prompt management of complications and disability management. 

And the meaningful engagement of persons affected by leprosy is not merely a component of elimination – it is the foundation on which elimination rests. 

Colleagues, 

The goal is clear: zero disease, zero disability, and zero stigma and discrimination. It is within reach. 

It is also a shared responsibility, demanding the clarity of your expertise, the commitment of Governments and partners, and the insight of people with lived experience. 

Behind every number you will discuss this week is a person. Let us keep that person at the centre of our work. 

I thank the WHO Regional Office for the Eastern Mediterranean for hosting this meeting in Cairo, and I thank you all for your commitment to this cause. 

I wish you a productive meeting. 

Thank you.